• 1
    Hericourt J, Richet C: De la serotherapie dans le traitement du cancer. C R Hebd Seances Acad Sci 1895; 121: 567569.
  • 2
    HimmelweitB (ed): The Collected Papers of Paul Ehrlich. London, England, Pergamon Press, 1957.
  • 3
    Pressman D, Keighley G: The zone of activity of antibodies as determined by the use of radioactive tracers: the zone of activity of nephrotoxic anti-kidney serum. J Immunol 1948; 59: 141146.
  • 4
    Pressman P, Korngold L: The in vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer 1953; 6: 619623.
  • 5
    Quinones J, Mizejewski G, Beierwaltes WH: Choriocarcinoma scanning using radiolabeled antibody to chorionic gonadotrophin. J Nucl Med 1971; 12: 6975.
  • 6
    Primus FJ, Wang RH, Goldenberg DM, et al: Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoem-bryonic antigen. Cancer Res 1973; 33: 29772982.
  • 7
    Goldenberg DM, Preston DF, Primus FJ, Hansen HJ: Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobin G. Cancer Res 1974; 34: 19.
  • 8
    Goldenberg DM, DeLand F, Kim E, et al: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 13841386.
  • 9
    Order SE, Klein JL, Ettinger D, et al: Use of isotopic immunoglobulin in therapy. Cancer Res 1980; 40: 30013007.
  • 10
    Köhler G, Milstein C: Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495497.
  • 11
    Diamond BA, Yelton DE, Scharff MD, Monoclonal antibodies: A new technique for producing serologic reagents. N Engl J Med 1981; 304: 13441349.
  • 12
    Waldmann TA: Monoclonal antibodies in diagnosis and therapy. Science 1991; 252: 16571662.
  • 13
    DeLand FH, Goldenberg DM: Radiolabeled antibodies: radiochemistry and clinical applications, in FreemanLM (ed): Freeman and Johnson's Clinical Radionuclide Imaging, Vol 3 update. Orlando. Florida, Grune & Stratton Inc, 1986, pp 19151992.
  • 14
    Ziegler EJ, Fisher CJ Jr. Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial: The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429436.
  • 15
    Haber E, Quertermous T, Matsueda GR, et al: Innovative approaches to plasminogen activator therapy. Science 1989; 243: 5156.
  • 16
    Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 31: 337342.
  • 17
    Hoffman T, Kenimer J, Stein KE: Regulatory issues surrounding therapeutic use of monoclonal antibodies: Points to consider in the manufacture of injectable products intended for human use, in Reis-feld RA, Sell S, (eds): Monoclonal Antibodies and Cancer Therapy, UCLA Symposia on Molecular and Cellular Biology, New Series, volume 27. New York City: Alan R Liss, 1985, pp 431440.
  • 18
    Kabat EA: The antibody combining site. Prog Immunol 1983; 5: 6785.
  • 19
    Kabat EA, Wu TT, Bilofsky H: Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites. J Biol Chem 1977; 252: 66096616.
  • 20
    Reisfeld RA, Cheresh DA: Human tumor antigens. Adv Immunol 1987; 40: 323377.
  • 21
    Stein R, Goldenberg DM: Prospects for the management of non-small-cell carcinoma of the lung with monoclonal antibodies. Chest 1991; 99: 14661476.
  • 22
    Old LJ: Cancer immunology: The search for specificity: GHA Clowes Memorial Lecture. Cancer Res 1981; 41: 361375.
  • 23
    Bradwell AR, Fairweather DS, Dykes PW, et al: Limiting factors in the localization of tumours with radiolabeled antibodies. Immunol Today 1985; 6: 163170.
  • 24
    Epenetos AA, Munro AJ, Stewart S, et al: Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987; 5: 18901899.
  • 25
    Lashford LS, Davies AG, Richardson RB, et al: A pilot study of 131–1 monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 1988; 61: 857868.
  • 26
    Riva P, Arista A, Tison V, et al: Intralesional radioimmunotherapy of malignant gliomas: an effective treatment in recurrent tumors. Cancer 1994, in press.
  • 27
    Schlom J: Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1986; 46: 32253238.
  • 28
    Goldenberg DM: Immunodiagnosis and immunodetection of colorectal cancer. Cancer Bull (Houston) 1978; 30: 213218.
  • 29
    GoldenbergDM (ed): Cancer Imaging with Radiolabeled Antibodies. Norwell. Massachusetts, Kluwer Publishers, 1990.
  • 30
    Perkins AC, Pimm MC: Immunoscintigraphy: Practical Aspects and Clinical Applications. New York City: Wiley-Liss, 1991.
  • 31
    Goldenberg DM, Larson SM: Radioimmunode-tection in cancer identification. J Nucl Med 1992; 33: 803814.
  • 32
    Maguire RT, Schmelter RF, Pascucci VL, et al: Immunoscintigraphy of colorectal adenocarcinoma: Results with site-specifically radiolabeled B72.3 (111In-CYT-103). Antib Immunoconjug Radio-pharm 1989; 2: 257269.
  • 33
    Patt YZ, Lamki LM, Shanken J, et al: Imaging with indium 111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol 1990; 8: 12461254.
  • 34
    Goldenberg DM, Goldenberg H, Sharkey RM, et al: Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 1989; 19: 262281.
  • 35
    Lechner P, Lind P, Binter G, et al: Anticarcinoembryonic antigen immunoscintigraphy with a 99mTc-Fab' fragment (Immu 4TM) in primary and recurrent colorectal cancer: A prospective study. Dis Colon Rectum 1993; 36: 930935.
  • 36
    Swayne LC, Goldenberg DM, Diehl WL, et al: SPECT anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases. Clin Nucl Med 1991; 16: 849852.
  • 37
    Pinsky CM, Sasso NL, Mojsiack JZ, et al: Results of a multicenter phase III clinical trial of Immu-RAID-CEA-Tc99m imaging in patients with colorectal cancer (abstr 410). Proc Am Soc Clin Oncol 1991; 10: 136.
  • 38
    Patt YZ, Podoloff D, Curley S, et al: Technetium 99m labeled MoAb anticarcinomaembryonic antigen (CEA) IMMU-4 for imaging of occult recurrent colorectal cancer in patients with rising serum CEA. J Clin Oncol 1994, in press.
  • 39
    Baum RP, Hertel A, Baew-Christow T, et al: Initial clinical results with a Tc-99m-labeled anti-AFP monoclonal antibody fragment in germ cell and liver tumors (abstr 613). J Nucl Med 1991; 32: 1053.
  • 40
    Bakir MA, Eccles S, Babich JW, et al: c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992; 33: 21542160.
  • 41
    Allan SM, Dean C, Fernando I, et al: Radioimmunolocalisation in breast cancer using the gene product of c-erb B2 as the target antigen. Br J Cancer 1993; 67: 706712.
  • 42
    Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 10021007.
  • 43
    Cuttitta F, Carney DN, Mulshine J, et al: Bom-besin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316: 823826.
  • 44
    Waldmann TA, Goldman CK, Bongiovanni KF, et al: Therapy of patients with human T-cell lympho-trophic virus I-induced adult T-cell leukemia with anti-Tac: A monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72: 18051816.
  • 45
    Wright PW, Bernstein ID: Serotherapy of malignant disease. Prog Exp Tumor Res 1980; 25: 140162.
  • 46
    Harris DT, Mastrangelo MJ: Serotherapy of cancer. Semin Oncol 1989; 16: 180198.
  • 47
    Janson CH, Tehrani M, Wigzell H, et al: Rational use of biological response modifiers in hematological malignancies: A review of treatment with interferon, cytotoxic cells and antibodies. Leuk Res 1989; 13: 10391046.
  • 48
    Oi VT, Morrison SL: Chimeric antibodies. Bio-Techniques 1986; 4: 214221.
  • 49
    Jones PT, Dear PH, Foote J, et al: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522525.
  • 50
    Shaw DR, Khazaeli MB, LoBuglio AF: Mouse/human chimeric antibodies to a tumor-associated antigen: Biologic activity of the four human IgG subclasses. J Natl Cancer Inst 1988; 80: 15531559.
  • 51
    Sears HF, Atkinson B; Mattis J, et al: Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; 1: 762765.
  • 52
    Mellstedt H, Frodin J-E, Masucci G: Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma. Oncology 1989; 3: 2532.
  • 53
    Cheung NK, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melonoma. J Clin Oncol 1987; 5: 14301440.
  • 54
    Houghton AN, Mintzer D, Cordon-Cardo C, et al: Mouse monoclonal antibody detecting GD3 gan-glioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985; 82: 12421246.
  • 55
    Goodman GE, Beaumier P, Hellstrom I, et al: Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 1985; 3: 340352.
  • 56
    Frodin JE, Harmenberg U, Biberfeld P, et al: Clinical effects of monoclonal antibodies (MAb 17–1A) in patients with metastatic colorectal carcinomas. Hybridoma 1988; 7: 309321.
  • 57
    Reisfeld RA: Potential of genetically engineered monoclonal antibodies for cancer immunotherapy. Pigment Cell Research 1992; (suppl 2): 109112.
  • 58
    Kunkel HG, Mannik M, Williams RC: Individual antigenic specificity of isolated antibodies. Science 1963; 140: 12181219.
  • 59
    Gell PGH, Kelus A: Anti-antibody or clone-product? Nature 1964; 201: 687689.
  • 60
    Nisonoff A, MacDonald AB, Hopper JE, et al: Quantitative studies of idiotypic antibodies. Fed Proc 1970; 29: 7277.
  • 61
    Geha RS: Regulation of the immune response by idiotype-antiidiotypic interactions. N Engl J Med 1981; 305: 2528.
  • 62
    Levy R, Miller RA: Antibodies in cancer therapy, in DeVitaVTJr, HellmanS, RosenbergSA (eds): Biologic Therapy of Cancer. Philadelphia, JB Lippincott, 1991, pp 512522.
  • 63
    Stevenson GT, Stevenson FK: Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 1975; 254: 714716.
  • 64
    Miller RA, Maloney DG, Warnke R, et al: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517522.
  • 65
    Brown SL, Miller RA, Horning SJ, et al: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651661.
  • 66
    Roitt IM, Thanavala YM, Male DK, et al: Anti-idiotypes as surrogate antigens: Structural considerations. Immunol Today 1985; 6: 265267.
  • 67
    Herlyn D, Ross AH, Koprowski H: Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 1986; 232: 100102.
  • 68
    Kennedy RC, Zhou E-M, Lanford RE, et al: Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J Clin Invest 1987; 80: 12171224.
  • 69
    Nepon GT, Nelson KA, Holbeck SL, et al: Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice. Proc Natl Acad Sci USA 1985; 81: 28642867.
  • 70
    Sikorska HM: Therapeutic applications of anti-idiotypic antibodies. J Biol Response Mod 1988; 7: 327358.
  • 71
    Herlyn D, Wettendorff M, Schmoll E, et al: Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc Natl Acad Sci USA 1987; 84: 80558059.
  • 72
    Mittelman A, Chen ZJ, Kageshita T, et al: Active specific immunotherapy in patients with melanoma: A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990; 86: 21362144.
  • 73
    Reisfeld RA, Yang HM, Muller B, et al: Promises, problems, and prospects of monoclonal antibody-drug conjugates for cancer therapy. Antib Immunoconjug Radiopharm 1989; 2: 217224.
  • 74
    Baldwin RW, Byers VS: Monoclonal antibodies and immunoconjugates for cancer treatment, in PinedoHM, ChabnerBA (eds): Cancer Chemotherapy and Biological Response Modifiers, Annual 9, New York City, Elsevier Science Publishers, 1987, pp 409431.
  • 75
    Koppel GA: Recent advances with monoclonal antibody drug targeting for the treatment of human cancer. Bioconjugate Chem 1990; 1: 1323.
  • 76
    Trail PA, Willner D, Lasch SJ, et al: Cure of xenografted human carcinomas by 96-doxorubicin immunoconjugates. Science 1993; 261: 212215.
  • 77
    Shih LB, Sharkey RM, Primus FJ, et al: Site-specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier. Int J Cancer 1988; 41: 832839.
  • 78
    Shih LB, Xuan H, Sharkey RM, et al: A fluorour-idine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model. Int J Cancer 1990; 46: 11011106.
  • 79
    Shih LB, Goldenberg DM, Xuan H, et al: Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier. Cancer Res 1991; 51: 41924198.
  • 80
    Takahashi T, Yamaguchi T, Kitamura K, et al: Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer 1988; 61: 881888.
  • 81
    FitzGerald D, Pastan I: Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 1989; 81: 14551463.
  • 82
    Vitetta ES, Thorpe PE: Immunotoxins, in De-VitaVTJr, HellmanS, RosenbergSA (eds): Biologic Therapy of Cancer. Philadelphia, JB Lippincott, 1991, pp 482495.
  • 83
    Hertler AA, Spitler LE, Frankel AE: Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv 1987; 4: 245253.
  • 84
    Oeltmann TN, Frankel AE: Advances in immunotoxins. FASEB J 1991; 5: 23342337.
  • 85
    Collier RJ: Diphtheria toxin: Mode of action and structure. Bacteriol Rev 1975; 39: 5485.
  • 86
    Spitler LE: Clinical studies: Solid tumors, in FrankelAE (ed): Immunotoxins. Norwell. Massachusetts. Kluwer Academic Publishers, 1988, pp 493514.
  • 87
    Blakey DC, Skilleter DN, Price RJ, et al: Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-paren-chymal cells in vitro and in vivo. Biochem Biophys Acta 1988; 968: 172178.
  • 88
    Vitetta ES, Stone M, Amlot P, et al: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51: 40524058.
  • 89
    Grossbard ML, Lambert JM, Goldmacher VS, et al: Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11: 726737.
  • 90
    Spitler LE, del Rio M, Khentigan A, et al: Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 1987; 47: 17171723.
  • 91
    Order SE: Systemic radiotherapy: The new frontier. Int J Radiat Oncol Biol Phys 1990; 18: 981992.
  • 92
    Siegel JA, Goldenberg DM, Sharkey RM, et al: Tumor and organ dosimetry for I-131-labeled LL2 (EPB2) monoclonal antibody in patients with B-cell lymphomas. Antib Immunoconjug Radiopharm 1991; 4: 649654.
  • 93
    Wessels BW, Rogus RD: Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984; 11: 638645.
  • 94
    Goldenberg DM: Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. Semin Nucl Med 1989; 19: 332339.
  • 95
    Buchsbaum DJ, Lawrence TS: New trends in the use of radioimmunoconjugates for the therapy of cancer, in RodwellJ (ed): Targeted Diagnosis & Therapy, volume III: Targeted Therapeutic Systems. New York City, Marcel Dekker Inc., 1990, pp 215255.
  • 96
    Larson SM, Leibel SA, Cheung N-KV: Radioisotope conjugates, in DeVitaVTJr, HellmanS, RosenbergSA (eds): Biologic Therapy of Cancer. Philadelphia, JB Lippincott, 1991, pp 496511.
  • 97
    Siegel JA, Pawlyk DA, Lee RE, et al: Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50: 1039s1042s.
  • 98
    Breitz HB, Weiden PL, Vanderheyden JL, et al: Clinical experience with rhenium-186-labeled antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992; 33: 10991109.
  • 99
    Goldenberg DM, Griffiths GL: Radioimmunotherapy of cancer: Arming the missiles. J Nucl Med 1992; 33: 11101112.
  • 100
    DeNardo SJ, DeNardo GL, O'Grady LF, et al: Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antib Immunoconjug Radiopharm 1988; 1: 1733.
  • 101
    Goldenberg DM, Horowitz JA, Sharkey RM, et al: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548564.
  • 102
    Lenhard RE Jr, Order SE, Spunberg JJ, et al: Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 12961300.
  • 103
    Vriesendorp HM, Herpst JM, Germack MA, et al: Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87–01. J Clin Oncol 1991; 9: 918928.
  • 104
    Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 459465.
  • 105
    Goodwin DA, Meares CF, McCall MJ, et al: Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988; 29: 226234.
  • 106
    Stickney DR, Slater JB, Kirk GA, et al: Bifunctional antibody: ZCE/CHA 111-indium BLEDTA-iv clinical imaging in colorectal carcinoma. Antib Immunoconjug Radiopharm 1989; 2: 113.
  • 107
    Hnatowich DJ, Virzi F, Rusckowski M: Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28: 12941302.
  • 108
    Paganelli G, Magnani P, Zito F, et al: Three-step monoclonal antibody tumor targeting in carci-noembryonic antigen-positive patients. Cancer Res 1991; 51: 59605966.
  • 109
    Goodwin D, Meares C, Diamanti C: Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur J Nucl Med 1984; 9: 209215.
  • 110
    Goldenberg DM, Sharkey RM, Ford E: Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J Nucl Med 1987; 28: 16041610.
  • 111
    Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459465.
  • 112
    DeNardo SJ, Mirick GR, Kroger LA. et al: The biologic window for ChL6 radioimmunotherapy. Cancer 1994, in press.
  • 113
    Traub UC, DeJager RL, Primus FJ, et al: Anti-idiotype antibodies in cancer patients receiving monoclonal antibody to carcinoembryonic antigen. Cancer Res 1988; 48: 40024006.
  • 114
    Haspel MV, McCabe RP, Pomato N, et al: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 1985; 45: 39513961.
  • 115
    James K: Human monoclonal antibodies and engineered antibodies in the management of cancer. Semin Cancer Biol 1990; 1: 243253.
  • 116
    Blumenthal RD, Sharkey RM, Snyder DJ, et al: Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1. Cancer Res 1988; 48: 54035406.
  • 117
    Blumenthal RD, Sharkey RM, Goldenberg DM: Dose escalation of radioantibody in a mouse model using recombinant human interleukin-1 and granulocyte-macrophage colony stimulating factor intervention to reduce myelosuppression. J Natl Cancer Inst 1992; 84: 399407.
  • 118
    Ledermann JA, Begent RH, Massof C, et al: A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response, Int J Cancer 1991; 47: 659664.
  • 119
    Primus FJ, Kelley EA, Hansen HJ, et al: “Sandwich”-type immunoassay for carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988; 34: 261264.
  • 120
    Hansen HJ, La Fontaine G, Newman ES, et al. Solving the problem of antibody interference in commercial “sandwich”-type immunoassays of carcinoembryonic antigen. Clin Chem 1989; 35: 146151.
  • 121
    Goldenberg DM, Sharkey RM, Primus FJ, et al: Neutron-capture therapy of human cancer: In vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system. Proc Natl Acad Sci USA 1984; 81: 560563.
  • 122
    Senter PD, Schreiber GJ, Hirschberg DL, et al: Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 1989; 49: 57895792.
  • 123
    Bagshawe KD, Springer CJ, Searle F, et al: A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988; 58: 700703.
  • 124
    Oldham R: Biotherapy: The IVth modality of cancer treatment. J Cell Physiol 1986; 4: 9199.